- Home
- BCRX
as of 12-17-2025 3:54pm EST
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 1.6B | IPO Year: | 1994 |
| Target Price: | $20.08 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.00 - $11.31 | Next Earning Date: | 11-03-2025 |
| Revenue: | $599,816,000 | Revenue Growth: | 45.38% |
| Revenue Growth (this year): | 40.2% | Revenue Growth (next year): | 7.71% |
Stock Insider Trading Activity of BioCryst Pharmaceuticals Inc. (BCRX)
Chief Legal Officer
Avg Cost/Share
$7.65
Shares
21,210
Total Value
$162,256.50
Owned After
315,726
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$7.65
Shares
19,770
Total Value
$151,240.50
Owned After
315,726
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$7.21
Shares
50,906
Total Value
$367,215.52
Owned After
315,726
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$7.10
Shares
91,004
Total Value
$646,510.62
Owned After
315,726
SEC Form 4
Director
Avg Cost/Share
$7.14
Shares
9,600
Total Value
$68,544.00
Owned After
30,642
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Barnes Alane P | BCRX | Chief Legal Officer | Dec 15, 2025 | Sell | $7.65 | 21,210 | $162,256.50 | 315,726 | |
| Barnes Alane P | BCRX | Chief Legal Officer | Dec 3, 2025 | Sell | $7.65 | 19,770 | $151,240.50 | 315,726 | |
| Barnes Alane P | BCRX | Chief Legal Officer | Dec 2, 2025 | Sell | $7.21 | 50,906 | $367,215.52 | 315,726 | |
| Barnes Alane P | BCRX | Chief Legal Officer | Dec 1, 2025 | Sell | $7.10 | 91,004 | $646,510.62 | 315,726 | |
| SANDERS MACHELLE | BCRX | Director | Nov 13, 2025 | Sell | $7.14 | 9,600 | $68,544.00 | 30,642 |
Compare BCRX vs Leading Stocks
See how BCRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BCRX BioCryst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.